ORCHID Annual Report 2023 - Flipbook - Page 22
Peer reviewed publications
Kim JS, Wray J, Ridout D, Plumb L, Nitsch D, Robb M, Marks SD (2024)
1% recipient cells. However, leukaemic patients benefit from methods
with greater sensitivity detecting as low as 0.001% cells (= microchimerism). A
drop in donor chimerism and a detectable mutation burden usually precedes
leukaemic relapse. This study will assess when detectable levels of
microchimerism and mutation burden in peripheral blood (PB) and BM can be
linked to an increased relapse risk indicating the use of therapeutic
interventions. PB samples will be further assessed to see if the relapse risk
can be monitored using PB only.
There is currently no data on which level of donor chimerism and mutation
burden post-BMT are associated with a significant relapse risk. Furthermore,
there is no systematic data for the use of therapeutic interventions to prevent
JMML relapse.
The first chapter of my PhD project has been completed which was examining
the significance of microchimerism in JMML patient post BMT.
Macrochimerism analysis has been added to the test repertoire as
characteristic chimerism patterns were observed in groups of relapse and
non-relapse JMML patients. Within the relapse group, a distinct chimerism
pattern was observed in the majority of patients. Monocyte and T cell
chimerism appeared to be key in this pattern. In relapse patients, recipient
chimerism in the monocytic cell lineage was rapidly increasing and was in fact
the PB-derived cell lineage with the highest percentage of recipient cells. The
T cell lineage displayed the lowest level of recipient chimerism. This is in
direct contrast to the monocyte and T cell recipient chimerism observed in
non-relapse cohorts where low monocytic and high T cell RC was observed.
Digital Profile:
ORCiD ID:0000-0003-0791-2291
Research Gate: https://www.researchgate.net/profile/Susanne-Kricke
Peer reviewed publications
Blanco E, Camps C, Bahal S, Kerai MD, Ferla MP, Rochussen AM, Handel
AE, Golwala ZM, Spiridou Goncalves H, Kricke S, Klein F, Zhang F,
Zinghirino F, Evans G, Keane TM, Lizot S, Kusters MAA, Iro MA, Patel SV,
Morris EC, Burns SO, Radcliffe R, Vasudevan P, Price A, Gillham O,
Valdebenito GE, Stewart GS, Worth A, Adams SP, Duchen M, André I, Adams
DJ, Santili G, Gilmour KC, Holländer GA, Davies EG, Taylor JC, Griffiths GM,
Thrasher AJ, Dhalla F, Kreins AY. (2024) Dominant negative variants in ITPR3
impair T cell Ca2+ dynamics causing combined immunodeficiency. Journal of
.
Experimental Medicine. 222(1): e20220979.
https://doi.org/10.1084/jem.20220979
Invited talks
Kricke S. The Role of Microchimerism Detection In Paediatric Transplantation
Science. Children9s Hospital of Philadelphia Virtual Grand Rounds,
September 2024
